Icariin as an emerging candidate drug for anticancer treatment: Current status and perspective - 08/12/22

Doi : 10.1016/j.biopha.2022.113991

Yufang Liu ^a,^b, Han Yang ^a,^b, Jie Xiong ^a,^b, Juanjuan Zhao ^a,^b, Mengmeng Guo ^a,^b, Jing Chen ^a,^b, Xu Zhao ^a,^b, Chao Chen ^a,^b, Zhixu He ^c, Ya Zhou ^a,^⁎ , Lin Xu ^a,^b,^⁎
^a Special Key Laboratory of Gene Detection ＆Therapy of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou 563000, China
^b Department of Immunology, Zunyi Medical University, Zunyi, Guizhou 563000, China
^c Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine of Zunyi Medical University, Zunyi, Guizhou 563000, China

^⁎Corresponding author.^⁎⁎Corresponding author at: Special Key Laboratory of Gene Detection ＆Therapy of Guizhou Province, Zunyi Medical University, Zunyi, Guizhou 563000, China.Special Key Laboratory of Gene Detection ＆Therapy of Guizhou Province, Zunyi Medical UniversityZunyiGuizhou563000China

Abstract

Icariin (ICA) is a kind of natural flavonoid compound monomer, which is derived from the extract of dried stems and leaves of Epimedium. Modern pharmacological studies have found that ICA has broad bioactive function in affecting the biological processes of a variety of cancers, including breast cancer, colorectal cancer, hepatocellular carcinoma, esophageal cancer and other cancers, which indicates that ICA has promising application value in the treatment of cancer patients in the future. Nevertheless, the targets and molecular mechanisms of ICA in cancer treatment have not been elucidated in detail. Therefore, in this review, we systematically summarizes the current research progress of ICA in a series of cancers. In particular, an emphasis is placed on the mechanism of ICA and its future development direction, aiming at providing relevant theoretical basis for the development and application of ICA in the future cancer treatment strategies.

Le texte complet de cet article est disponible en PDF.

Highlights

•	Icariin is a kind of natural flavonoid glycosides with many pharmacological activities.
•	Icariin has broad inhibitory effect on breast cancer, colon cancer, hepatocellular carcinoma and other cancers.
•	Icariin can enhance the sensitivity of tumor cells to radiotherapy and chemotherapy.

Le texte complet de cet article est disponible en PDF.

Keywords : Active ingredients of Traditional Chinese Medicine, Icariin, Cancer, Growth, Apoptosis, Migration, Invasion, Drug resistance

Abbreviations : 5-FU, AD, ALDH2, APL, ATO, Bcl-2, Caspase-3, CPNE1, CSCs, DCFH-DA, DMSO, EGFR, EMT, ERK, FBP1, GPER1, GSH, GSK-3β, ICA, ICT, NADPH, ROS, SIRT6, TGF-β, TCM

Plan

Introduction

Epimedium and Icariin

Hepatocelluar carcinoma

Conclusion and perspectives

Credit authorship contribution statement

Export

Vol 157

Article 113991- janvier 2023 Retour au numéro

Article précédent

Drug repurposing: Clemastine fumarate and neurodegeneration
Jiahui Zhu, Rong Ma, Gang Li

| Article suivant

CD147 and MMPs as key factors in physiological and pathological processes
Rezvan Asgari, Asad Vaisi-Raygani, Mohammad Sajad Emami Aleagha, Pantea Mohammadi, Mitra Bakhtiari, Nahid Arghiani

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Icariin as an emerging candidate drug for anticancer treatment: Current status and perspective - 08/12/22

Abstract

Highlights

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL